Last updated: September 23, 2026
Quizartinib dihydrochloride, marketed as Vanflyta by Daiichi Sankyo, is a targeted FLT3 inhibitor for adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication-positive, or FLT3-ITD-positive. Its commercial opportunity is concentrated in newly diagnosed AML, where it competes with midostaurin and, in selected treatment settings, gilteritinib.
The drug has a differentiated clinical profile because the QUANTUM-First trial showed an overall-survival benefit when quizartinib was added to induction and consolidation chemotherapy and continued as maintenance. The main commercial constraints are its narrow biomarker population, competition from established FLT3 inhibitors, the need for combination treatment, and the absence of a broad relapsed/refractory indication.
What is quizartinib dihydrochloride and how does it work?
Quizartinib dihydrochloride is the oral dihydrochloride salt of quizartinib, a selective type II FLT3 inhibitor. It inhibits FLT3-ITD signaling, which drives proliferation in a substantial subset of AML cases.
The approved regimen combines quizartinib with standard cytarabine- and anthracycline-based induction and consolidation chemotherapy, followed by quizartinib maintenance in patients who achieve remission. The FDA approved Vanflyta on July 20, 2023, for adults with newly diagnosed AML that is FLT3-ITD-positive, in combination with cytarabine and anthracycline induction and consolidation and as maintenance monotherapy after consolidation.[1]
What population can receive Vanflyta?
The addressable population is narrower than the total AML market:
| Market filter |
Commercial implication |
| Newly diagnosed AML |
Excludes most relapsed or refractory AML patients |
| FLT3-ITD-positive disease |
Limits treatment to a molecularly defined subgroup |
| Adults |
No pediatric commercial opportunity under the current US label |
| Patients eligible for intensive chemotherapy |
Excludes many older or medically unfit patients |
| Combination and maintenance use |
Creates longer treatment duration but adds regimen complexity |
FLT3 mutations occur in approximately 25% to 30% of AML cases, with FLT3-ITD representing the principal target population for quizartinib.[2] The commercially relevant population is smaller because some patients are not candidates for intensive induction or do not reach maintenance therapy.
What clinical evidence supports quizartinib’s market position?
The QUANTUM-First Phase 3 trial randomized adults with newly diagnosed FLT3-ITD-positive AML to standard chemotherapy plus quizartinib or chemotherapy plus placebo. Median overall survival was 31.9 months with quizartinib compared with 15.1 months with placebo, with a hazard ratio of 0.78.[3]
The trial did not produce a material improvement in the initial complete-remission rate. Complete remission was approximately 55% in both study arms. The commercial value therefore depends on the survival benefit, continued therapy after remission, and the ability to maintain patients on treatment.
How does quizartinib compare with midostaurin?
Midostaurin, marketed as Rydapt by Novartis, is approved for newly diagnosed AML with FLT3 mutations, including FLT3-ITD and FLT3-TKD mutations. Quizartinib is more selective for FLT3-ITD but has a narrower label.
| Factor |
Quizartinib |
Midostaurin |
| Brand |
Vanflyta |
Rydapt |
| Sponsor |
Daiichi Sankyo |
Novartis |
| Main AML setting |
Newly diagnosed FLT3-ITD-positive AML |
Newly diagnosed FLT3-mutated AML |
| Mutation coverage |
Primarily FLT3-ITD |
FLT3-ITD and FLT3-TKD |
| Maintenance |
Included in the approved regimen |
Not positioned identically as a dedicated maintenance course |
| Key trial |
QUANTUM-First |
RATIFY |
| Differentiation |
Overall-survival benefit in QUANTUM-First |
Established first-mover position and broader FLT3 mutation coverage |
The competitive issue is practical rather than purely clinical. Physicians may select quizartinib when a patient has confirmed FLT3-ITD disease and is fit for intensive chemotherapy. Midostaurin retains an advantage where clinicians prefer broader FLT3 mutation coverage or have established institutional protocols.
What is the FDA regulatory status of Vanflyta?
Vanflyta has full FDA approval for newly diagnosed FLT3-ITD-positive AML in adults when used with intensive chemotherapy and as post-consolidation maintenance.[1]
The FDA label includes a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest. The drug is distributed through a restricted program requiring cardiac monitoring and attention to electrolyte abnormalities and interacting medicines.[1]
The safety controls can reduce prescribing friction and increase monitoring costs. They also create a barrier to casual substitution with another FLT3 inhibitor, since treatment requires a defined clinical protocol.
What is the European regulatory position?
The European Commission authorized Vanflyta for newly diagnosed FLT3-ITD-positive AML in adults in 2023, following a positive opinion from the European Medicines Agency.[4] Japan authorized quizartinib earlier for FLT3-ITD-positive AML, giving Daiichi Sankyo a longer commercial history in its home market.
Regulatory expansion has centered on the same newly diagnosed population. A broad relapsed/refractory indication would materially increase market size, but quizartinib’s commercial profile remains tied primarily to frontline treatment.
How large is the quizartinib market opportunity?
The global AML market is expanding through increased molecular testing, targeted therapies, maintenance treatment, and improved survival. Quizartinib’s addressable market is a targeted segment rather than the full AML population.
A practical market-sizing framework is:
- Total adult newly diagnosed AML cases.
- Patients tested for FLT3 mutations.
- FLT3-ITD-positive patients.
- Patients fit for intensive chemotherapy.
- Patients treated within approved geographies.
- Patients who continue into consolidation and maintenance.
The largest commercial markets are the United States, Japan, and major European countries. The United States has the highest per-patient revenue potential but also the strongest payer, safety-monitoring, and competitor pressures.
What is the revenue trajectory for Vanflyta?
Daiichi Sankyo reported Vanflyta as a growth product following the US launch in 2023. Early revenue was limited by the timing of launch, diagnostic identification, treatment-center adoption, and the need to integrate the drug into induction protocols. Revenue growth should be measured through prescription volume, new-patient starts, duration of maintenance therapy, and geographic expansion rather than through the AML prevalence figure alone.
The commercial trajectory has four phases:
| Phase |
Revenue driver |
| Initial launch |
Academic-center adoption and FLT3 testing |
| Protocol adoption |
Inclusion in hospital AML pathways |
| Maintenance expansion |
Longer treatment duration after remission |
| Geographic scaling |
European and Asian reimbursement and uptake |
Maintenance is strategically important. A patient who remains on quizartinib after induction and consolidation can generate substantially more revenue than a patient who receives only the induction and consolidation portions of therapy.
Daiichi Sankyo does not publicly disclose a standalone global Vanflyta profit-and-loss statement. Reported product sales should therefore be interpreted alongside launch timing, foreign-exchange movements, inventory, and regional reimbursement.
What patents protect quizartinib and when does exclusivity end?
Quizartinib protection is expected to rely on a layered estate covering the active compound, pharmaceutical salts, formulations, dosing regimens, and methods of treating FLT3-mutated AML. The relevant patent term depends on the individual patent, terminal disclaimers, patent-term adjustment, pediatric extensions, and regulatory patent-term extension.
The key US exclusivity milestones are:
| Protection category |
Commercial relevance |
| New chemical entity exclusivity |
FDA exclusivity for the active ingredient |
| Composition-of-matter patents |
Core protection against generic quizartinib |
| Salt and solid-state patents |
Protection for dihydrochloride and related pharmaceutical forms |
| Formulation patents |
Protection for tablets, excipients, or release characteristics |
| Method-of-use patents |
Protection for FLT3-ITD AML treatment, combination therapy, or maintenance |
| Regulatory exclusivity |
Limits certain abbreviated applications during the exclusivity period |
The FDA granted Vanflyta orphan-drug designation, which generally provides seven years of US orphan exclusivity from approval, subject to statutory exceptions.[1] The seven-year period places the end of orphan exclusivity in 2030, although it does not prevent all types of competing products or address patent rights.
The core patent estate may extend beyond regulatory exclusivity. The commercial launch date for a generic depends on the surviving composition, formulation, and method-of-use patents, as well as the outcome of any Paragraph IV litigation.
What is the Orange Book status of quizartinib?
Vanflyta is an FDA-approved small-molecule drug and is eligible for Orange Book patent listing. The Orange Book can include patents covering the drug substance, drug product, and approved methods of use.
The commercial significance of an Orange Book listing is that an ANDA applicant must certify against listed patents. A Paragraph IV certification can trigger litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework.[5]
The exact list of active Orange Book patents and their expiration dates changes as FDA records are updated. Patent-term adjustment and pediatric exclusivity can also alter the effective date of generic approval. A definitive launch model should use the current FDA Orange Book entry rather than relying on the original approval date.
Are there Paragraph IV challenges or generic launch risks?
No major publicly reported US Paragraph IV dispute had materially changed Vanflyta’s commercial outlook through mid-2024. The principal generic risk is likely to arise when the earliest commercially meaningful composition or product patents approach expiration.
Generic entry risk is moderate in the long term and limited in the near term. Three factors support this assessment:
- Quizartinib has a narrow biomarker-defined market.
- The product is used within a complex AML treatment pathway.
- A generic applicant may need to address multiple listed patents and approved-use restrictions.
The risk increases if an ANDA applicant can launch with a label that omits protected maintenance or combination indications, or if a court invalidates the relevant composition or product patent. Authorized generic or settlement arrangements could also affect the timing and price erosion.
How strong is the quizartinib patent estate?
The estate is commercially stronger when composition-of-matter protection remains enforceable. Formulation and method-of-use patents generally provide less durable protection because generic companies may design around them or use a skinny label.
| Patent layer |
Relative strength |
| Composition of matter |
Usually strongest |
| Pharmaceutical salt or solid form |
Potentially strong, but vulnerable to validity and enablement challenges |
| Tablet formulation |
Moderate; design-around risk is higher |
| Combination treatment |
Moderate; label and infringement issues are significant |
| Maintenance method |
Moderate to strong if the approved regimen is specifically claimed |
| Manufacturing process |
Useful for supply protection, but usually does not block a non-infringing generic process |
Manufacturing patents may protect crystallization, salt formation, impurity control, or scalable synthesis. These rights can raise development costs but usually do not prevent a generic company from using an alternative process.
What licensing deals and companies control quizartinib?
Daiichi Sankyo controls the principal global commercial rights to Vanflyta. Quizartinib originated from Ambit Biosciences, which Daiichi Sankyo acquired in 2014 for approximately $410 million upfront plus potential contingent payments.[6]
The transaction gave Daiichi Sankyo control of quizartinib and Ambit’s FLT3-focused oncology portfolio. The acquisition reduced reliance on a third-party license for commercialization and placed development, manufacturing, and regulatory strategy under one sponsor.
The competitive landscape includes:
| Company |
Product |
Relevance |
| Daiichi Sankyo |
Quizartinib/Vanflyta |
FLT3-ITD frontline AML |
| Novartis |
Midostaurin/Rydapt |
FLT3-mutated frontline AML |
| Astellas |
Gilteritinib/Xospata |
Relapsed or refractory FLT3-mutated AML |
| Generic manufacturers |
Future quizartinib products |
Long-term price pressure after patent and exclusivity loss |
What litigation, settlement, and biosimilar risks affect quizartinib?
Quizartinib is a synthetic small molecule, not a biologic. Biosimilar risk does not apply. The relevant future competition is conventional generic competition through the ANDA pathway.
Potential litigation would likely involve:
- Invalidity or non-infringement challenges to composition patents.
- Challenges to salt, crystalline-form, or formulation patents.
- Disputes over method-of-use patents.
- Hatch-Waxman litigation following a Paragraph IV certification.
- Patent-term-adjustment or pediatric-exclusivity calculations.
No major settlement agreement had been publicly identified as changing the US launch timetable through mid-2024. A future settlement could permit an authorized generic, an agreed entry date, or a license with supply restrictions.
What generic launch scenarios exist for Vanflyta?
Three launch scenarios are commercially relevant:
Early negotiated entry
A generic company settles with Daiichi Sankyo and launches before the final patent expiry. Price erosion would depend on whether the launch is an authorized generic or an independent ANDA product.
Litigation-driven entry
A court finds a key patent invalid or not infringed. This scenario can produce an earlier launch and sharper revenue decline.
Patent-expiry entry
Generic companies wait for the core patent estate to expire. This usually creates the most predictable launch date but still may involve a staggered rollout because of manufacturing and regulatory readiness.
Because Vanflyta serves a relatively narrow population, the initial number of generic entrants may be smaller than for high-volume primary-care drugs. Revenue erosion could still be substantial because oral oncology products are exposed to specialty-pharmacy substitution and payer formulary pressure.
How does quizartinib compare with gilteritinib?
Quizartinib and gilteritinib target overlapping FLT3 biology but occupy different treatment settings.
| Factor |
Quizartinib |
Gilteritinib |
| Brand |
Vanflyta |
Xospata |
| Main approved AML setting |
Newly diagnosed FLT3-ITD-positive AML |
Relapsed or refractory FLT3-mutated AML |
| Commercial role |
Frontline plus maintenance |
Salvage and later-line therapy |
| Sponsor |
Daiichi Sankyo |
Astellas |
| Market overlap |
Limited in label-compliant use |
Limited in label-compliant use |
The two products are more complementary than directly substitutable under their current US labels. Off-label use, clinical trials, transplant strategy, and evolving treatment guidelines can create practical overlap.
Key Takeaways
- Quizartinib is a targeted frontline AML product with a narrow FLT3-ITD-positive population.
- The QUANTUM-First overall-survival result is the main commercial differentiator.
- Maintenance therapy increases treatment duration and revenue per successfully treated patient.
- Midostaurin is the main frontline competitor; gilteritinib is more relevant in relapsed or refractory disease.
- FDA approval occurred in July 2023, with European authorization in 2023 and earlier Japanese approval.
- Orphan exclusivity is expected to run into 2030, while patent protection may extend beyond that date.
- Near-term generic risk is limited, but long-term risk depends on the strength and expiration dates of composition, formulation, and method-of-use patents.
- Quizartinib has no biosimilar risk because it is a small-molecule drug.
- Daiichi Sankyo’s acquisition of Ambit Biosciences gave it control of the product and its core development program.
- Revenue depends on FLT3 testing, intensive-chemotherapy eligibility, treatment-center adoption, maintenance persistence, and reimbursement.
FAQs About Quizartinib Dihydrochloride
Is quizartinib approved for relapsed AML?
The US approval is for newly diagnosed FLT3-ITD-positive AML in adults receiving intensive chemotherapy and maintenance treatment. It is not broadly approved in the United States for relapsed or refractory AML.
Does quizartinib treat FLT3-TKD AML?
Quizartinib’s commercial label is focused on FLT3-ITD-positive AML. Midostaurin has broader approved FLT3 mutation coverage, including FLT3-TKD disease.
Is Vanflyta chemotherapy or targeted therapy?
Vanflyta is an oral targeted FLT3 inhibitor. It is administered with intensive chemotherapy during induction and consolidation and as maintenance after consolidation.
What is the main safety concern with quizartinib?
QT prolongation and the risk of torsades de pointes or cardiac arrest are the principal labeled safety concerns. The FDA requires cardiac monitoring and restricted distribution controls.
Can a generic company launch quizartinib before 2030?
A generic company could potentially launch before 2030 through a successful patent challenge, a settlement license, or an authorized-generic arrangement. Orphan exclusivity and patent expiry are separate legal barriers.
References
- U.S. Food and Drug Administration. (2023). Vanflyta (quizartinib) prescribing information.
- Dohner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Mullighan, C. G., Papaemmanuil, E., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H. F., and Lowenberg, B. (2022). Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood, 140(12), 1345-1377.
- Erba, H. P., Montesinos, P., Kim, H. J., Patkowska, E., Vrhovac, R., Dohner, H., et al. (2023). Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD-positive acute myeloid leukemia. The Lancet, 401(10388), 1571-1583.
- European Medicines Agency. (2023). Vanflyta: EPAR product information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Daiichi Sankyo Company, Limited. (2014). Daiichi Sankyo to acquire Ambit Biosciences.
